FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
|Videos|September 20, 2016
Hidden Costs for Patients Starting a Specialty Drug Regimen
Author(s)Lauren Santye, Assistant Editor
Marc O'Connor, COO and chief strategy officer at Curant Health, discusses the out-of-pocket costs that can emerge for patients starting a specialty medication regimen.
Advertisement
Marc O'Connor, COO and chief strategy officer at Curant Health, discusses the out-of-pocket costs that can emerge for patients starting a specialty medication regimen.
Advertisement
Related to this article
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
Engineered Stem Cell Therapy Reverses New-Onset T1D in Mice by Reprogramming T Cells
3
CagriSema Tops Tirzepatide 5 mg for Weight Loss in REIMAGINE 5
4
CKD Prevalence Unmoved Despite Billions in Virtual Care
5